|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 1. Histological characterization of the Dlx1/Dlx2 mutant retina.
(A,B) Cresyl Violet staining of Dlx1/Dlx2 mutant and wild-type
retinas at E18.5. The mutant displays a reduced GCL (B, arrows) but the
remainder of the retina appears spared. (C-F) Expression of BRN3a (C,D) and
BRN3b (E,F) in mutant and wild-type retina. Decreased numbers of BRN3a and
BRN3b immunoreactive cells (C,E, arrows) indicate that fewer RGCs are present
in the mutants. (G-J) Expression of SIX3 and PAX6 in mutant and wild-type
retina. SIX3 and PAX6 are expressed in fewer cells in the mutant GCL than in
the wild type (G,I, arrows). Expression of SIX3 and PAX6 in the neuroblastic
layer appears unaffected in mutants (G,H,I,J, asterisks). (K-N) Expression of
amacrine cell markers in the mutant and wild-type retina. (K,L) Syntaxin
expression appears unchanged. (M,N) Calretinin immunoreactive cells are
expressed in the mutant retina in numbers similar to those of wild type. (O-R)
Horizontal cell markers are expressed in normal number and position in the
Dlx1/Dlx2 mutants. Expression of NF165 (O,P, arrows) and PROX1 (Q,R,
asterisks) are unaffected in the mutant. PROX1 expression in the GCL (Q,R,
arrows) supports normal AII amacrine cell development. Scale bars: 250 µm
in B; 50 µm in I,J,Q,R.
|
